We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Letrozole in Postmenopausal Women at Increased Risk for Breast Cancer

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified January 2007 by Dana-Farber Cancer Institute.
Recruitment status was:  Active, not recruiting
ClinicalTrials.gov Identifier:
First Posted: January 24, 2006
Last Update Posted: January 19, 2007
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Beth Israel Deaconess Medical Center
Brigham and Women's Hospital
Massachusetts General Hospital
Information provided by:
Dana-Farber Cancer Institute
The purpose of this study to see what happens to breast density in healthy postmenopausal women after treatment with letrozole in one year, compared with treatment with placebo for one year. Other goals of the study include determining if there is a connection between estrogen level and breast density for women in the study and collecting information about the quality of life of those taking part in the study.

Condition Intervention Phase
Post-Menopausal Breast Cancer Drug: Letrozole Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Double
Primary Purpose: Prevention
Official Title: A Randomized Feasibility Study of Letrozole in Postmenopausal Women at Increased Risk for Development of Breast Cancer as Evidenced by High Breast Density

Resource links provided by NLM:

Further study details as provided by Dana-Farber Cancer Institute:

Primary Outcome Measures:
  • To determine the proportion of women with breast density of > grade 4 who have a decrease in breast density of at least one grade after treatment with letrozole for one year.

Secondary Outcome Measures:
  • To determine if the decrease in breast density grade is sustained one year after cessation of therapy
  • to determine if there is a correlation between plasma estrogen profile and breast density at baseline
  • to determine the percentage of subjects with breast tissue hyperplasia and atypical hyperplasia before and after therapy
  • to assess change in estrogen profile from baseline and at 1 year and 1 year after cessation of therapy
  • to assess the general safety of the utilization of letrozole in healthy post-menopausal women for one year
  • to compare the effects on menopause-specific quality of life.

Estimated Enrollment: 60
Study Start Date: October 2005
Detailed Description:
  • Patients will be randomized into one of two study groups. Group 1 will receive letrozole and Group 2 will receive placebo. This is a double-blind trial so neither the patient or the doctor will know what treatment group they are assigned to.
  • If the patient is in Group 1 they will take letrozole tablets orally once a day with food for one year. Patients in Group 2 will take a placebo tablet orally once a day with food for one year.
  • Patients in both groups will also be given calcium tablets (500mg) and vitamin D tablets (400IU) once a day for one year.
  • After the initial screening visits, the patient will return to the clinic at 3, 6, 9 and 12 months (a total of up to 6 visits in the first year). There will also be two follow-up visits at 18 and 24 months. For the 3, 9 and 18 month visits, telephone contact instead of a clinic visit is allowed.
  • The following tests and procedures will be performed during these visits:

evaluation of side effects; routine blood tests(6, 12, and 24 month visits); urine sample (6 and 12 month visits); complete physical exam including breast exam (12 and 24 month visits); mammogram (12 and 24 month visits); bone marrow density x-ray test (12 and 24 month visits); standard x-rays of the lower back and chest (12 month visit); and a questionnaire about how the patient is feeling (12 and 24 month visits).

  • The length of participation in this study is for 1 year of study treatment followed by 1 year of follow-up.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Postmenopausal status defined as: women >55 years of age-no spontaneous menses for at least 12 months; in women < 55 years-no spontaneous menses within the past 12 months and with an FSH level >34.4 IU/I; bilateral oophorectomy
  • If subject had prior invasive breast cancer it must have been surgically removed at the time of orginal diagnosis with no evidence of metastases and the primary tumor may be receptive negative, positive or equivocal
  • Baseline mammogram (within 6 months) indicating mammographic density occupying >25% (grade 4/5, 5/6 or 6/6) of the breast tissue
  • Baseline breast examination demonstrating no clinical evidence of breast cancer
  • Acceptable quality DEXA of the L2-L4 postero-anterior (PA) spine and hup must be performed 6 months of randomization
  • Subject is willing and able to complete the quality of life questionnaire in either English or French

Exclusion Criteria:

  • Mammogram suspicious for breast cancer (unless subsequently ruled out)
  • Patient's with prior malignancies are eligible unless they have metastatic disease
  • Uncontrolled metabolic or endocrine disease, cardiovascular disease or malabsorption syndrome
  • Current chemotherapy or immunotherapy
  • Hormone replacement therapy or Evista (raloxifene) discontinued less than three months before baseline mammogram
  • Tamoxifen therapy discontinued less than six months prior to randomization
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00280930

United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02215
Sponsors and Collaborators
Dana-Farber Cancer Institute
Beth Israel Deaconess Medical Center
Brigham and Women's Hospital
Massachusetts General Hospital
Principal Investigator: Paul Goss, MD, PhD Massachusetts General Hospital
  More Information

ClinicalTrials.gov Identifier: NCT00280930     History of Changes
Other Study ID Numbers: 05-183
First Submitted: January 23, 2006
First Posted: January 24, 2006
Last Update Posted: January 19, 2007
Last Verified: January 2007

Keywords provided by Dana-Farber Cancer Institute:
breast cancer

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Antineoplastic Agents
Aromatase Inhibitors
Steroid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs